Mammary Cell News Volume 7.07 | Feb 26 2015

Graphene Oxide Selectively Targets Cancer Stem Cells, across Multiple Tumor Types: Implications for Non-Toxic Cancer Treatment, via “Differentiation-Based Nano-Therapy”
Scientists showed that graphene oxide effectively inhibits tumor-sphere formation in multiple cell lines, across six different cancer types, including breast, ovarian, prostate, lung and pancreatic cancers, as well as glioblastoma. [Oncotarget] Full Article | Press Release

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo
The androgen receptor (AR) is expressed in up to one third of triple-negative breast cancer (TNBC) and investigators found that all AR⁺ TNBC primary tumors tested display nuclear localization of AR, indicative of transcriptionally active receptors. [Mol Cancer Ther] Abstract | Press Release

Neuropeptide Y Y₁ Receptors Meditate Targeted Delivery of Anticancer Drug Encapsulating Nanoparticles to Breast Cancer Cells with High Selectivity and Its Potential for Breast Cancer Therapy
A neuropeptide Y Y₁ receptors ligand PNBL-NPY, as a novel targeted molecule, was conjugated with anticancer drug doxorubicin encapsulating albumin nanoparticles to investigate the effect of Y₁ receptors on the delivery of drug loaded nanoparticles to breast cancer cells and its potential for breast cancer therapy. [ACS Appl Mater Interfaces] Abstract

DNA Damage Response Markers Are Differentially Expressed in BRCA-Mutated Breast Cancers
Researchers investigated differential expression of a large panel of DNA repair markers to characterize DNA repair mechanisms in BRCA-associated tumors compared to sporadic tumors in an attempt to characterize these tumors in routine practice. [Breast Cancer Res Treat] Abstract | Full Article

The Mammalian Target of Rapamycin Complex 1 (mTORC1) in Breast Cancer: The Impact of Estrogen Receptor and HER2 Pathways
Scientists investigated the expression of mTORC1 in breast cancer (BC) and correlated it with key clinicopathological and molecular features of BC especially to proteins related to estrogen receptor and HER2 pathways in different BC classes. [Breast Cancer Res Treat] Abstract

Hierarchical Clustering of Breast Cancer Methylomes Revealed Differentially Methylated and Expressed Breast Cancer Genes
Investigators conducted whole-genome bisulfite sequencing to determine the DNA methylomes of normal breast, fibroadenoma, invasive ductal carcinomas and MCF7. The emergence, disappearance, expansion and contraction of kilobase-sized hypomethylated regions and the hypomethylation of the megabase-sized partially methylated domains are the major forms of methylation changes observed in breast tumor samples. [PLoS One] Full Article

Notch4 Signaling Confers Susceptibility to TRAIL Induced Apoptosis in Breast Cancer Cells
Researchers investigated TNF-related apoptosis-inducing ligand (TRAIL) sensitivity in tumor cells following the modulation of Notch (1 and 4) activity using siRNA-mediated depletions or ectopic expression of GFP-tagged constructs of the intracellular domains of Notch1 or Notch4. [J Cell Biochem] Abstract

IL-6 Originated from Breast Cancer Tissue-Derived Mesenchymal Stromal Cells May Contribute to Carcinogenesis
Scientists investigated the effect of IL-6 in the tumor microenvironment on carcinogenesis. Healthy breast tissue-derived stromal cells and malign breast tissue-derived stromal cells were co-cultured with MCF-7 (human breast adenocarcinoma cell line) cells using semipermeable membranes. [Tumor Biol] Abstract

CLINICAL RESEARCH

Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study
Investigators tested whether combining bevacizumab, an anti-vascular endothelial growth factor treatment, with endocrine therapy (ET) could potentially delay the emergence of resistance to ET. [J Clin Oncol] Abstract

Targeted T Cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Researchers reported a Phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions of anti-CD3 x anti-HER2 bispecific antibody armed anti-CD3 activated T cells in combination with low dose interleukin 2 and granulocyte-macrophage-colony stimulating factor to determine safety, maximum tolerated dose, technical feasibility, T cell trafficking, immune responses, time to progression, and overall survival. [Clin Cancer Res] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

MD Anderson Receives $22.3 Million in CPRIT Research Funding
The University of Texas MD Anderson Cancer Center has received more than $22 million in research grants from the Cancer Prevention and Research Institute of Texas (CPRIT). The CPRIT awards will go toward studies in the areas of breast, skin, prostate, pancreas, colon and lung cancers in adults; leukemia and brain cancer in children, and for studies aimed at preventing colon cancer and lung cancer. [The University of Texas MD Anderson Cancer Center] Press Release

From our sponsor:
Looking for ALDH⁺ cancer stem cells? Watch a video to see how ALDEFLUOR™ can help.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Breast Cancer Biology (University of Pennsylvania)

Clinician Scientist (National University of Singapore)

Postdoctoral Associate – LincRNAs in Tumorigenesis (Fox Chase Cancer Center)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Postdoctoral Positions – Cancer Bioengineering and Cancer Biology (University of Minnesota)

Director of Research (Dr. Susan Love Research Foundation)

Postdoctoral Research Fellow – Post-Transcriptional Gene Regulation Governing Cancer Cell Behavior (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.